

CORRECTION

Correction to: Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan

Tomoko Kashiwagi¹ · Yukiko Okada¹ · Ken Nomoto¹

Published online: 10 April 2018
© Springer International Publishing AG, part of Springer Nature 2018

Correction to: *Pediatr Drugs* 2018 20(1):97–104
<https://doi.org/10.1007/s40272-017-0264-y>

Page 98, Section 2.1: The following sentence, which previously read:

“Newborns, infants, or young children aged 24 months and under who have Down syndrome, and children \leq 24 months of age without a current hs-CHD if they had

experienced persistent respiratory symptoms or regular outpatient treatment due to a respiratory tract infection in previous RSV seasons were also eligible for the study.”

Should read:

“Newborns, infants, or young children aged 24 months and under who have Down syndrome (without a current hs-CHD) were also eligible for the study.”

The original article can be found online at <https://doi.org/10.1007/s40272-017-0264-y>.

✉ Ken Nomoto
ken.nomoto@abbvie.com

¹ AbbVie GK, Mita 3-5-27, Minato-ku, Tokyo 108-6302, Japan